Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- ₹426.28 million
- Book Value:
- Revenue TTM:
- ₹4.15 billion
- Operating Margin TTM:
- Gross Profit TTM:
- ₹1.88 billion
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Ind-Swift Limited had its IPO on under the ticker symbol INDSWFTLTD.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Ind-Swift Limited has a staff strength of 1,129 employees.
Shares of Ind-Swift Limited opened at ₹7.75 at the start of the last trading session i.e. 2023-05-28.
The stocks traded within a range of ₹7.65 - ₹8.45, and closed at ₹8.4.
This is a +4.35% increase from the previous day's closing price.
A total volume of 58,946 shares were traded at the close of the day’s session.
In the last one week, shares of Ind-Swift Limited have slipped by -1.75%.
Ind-Swift Limited's Key Ratios
Ind-Swift Limited has a market cap of ₹426.28 million, indicating a price to book ratio of 0 and a price to sales ratio of 0.1388.
In the last 12-months Ind-Swift Limited’s revenue was ₹4.15 billion with a gross profit of ₹1.88 billion and an EBITDA of ₹478.62 million. The EBITDA ratio measures Ind-Swift Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Ind-Swift Limited’s operating margin was 4.8% while its return on assets stood at 0% with a return of equity of 0%.
In Q4, Ind-Swift Limited’s quarterly earnings growth was a positive 0% while revenue growth was a positive 2.1%.
Ind-Swift Limited’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at ₹-5.98 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Ind-Swift Limited’s profitability.
Ind-Swift Limited stock is trading at a EV to sales ratio of 2.6258 and a EV to EBITDA ratio of 21.2447. Its price to sales ratio in the trailing 12-months stood at 0.1388.
Ind-Swift Limited stock pays annual dividends of ₹0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- ₹6.23 billion
- Total Liabilities
- ₹7.32 billion
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Ind-Swift Limited ended 2023 with ₹6.23 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹6.23 billion while shareholder equity stood at ₹-7463483000.00.
Ind-Swift Limited ended 2023 with ₹0 in deferred long-term liabilities, ₹7.32 billion in other current liabilities, in common stock, ₹0 in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹138.33 million and cash and short-term investments were ₹0. The company’s total short-term debt was ₹0 while long-term debt stood at ₹6.22 billion.
Ind-Swift Limited’s total current assets stands at ₹2.32 billion while long-term investments were ₹0 and short-term investments were ₹0. Its net receivables were ₹878.68 million compared to accounts payable of ₹2.02 billion and inventory worth ₹689.31 million.
In 2023, Ind-Swift Limited's operating cash flow was ₹0 while its capital expenditure stood at ₹0.
Comparatively, Ind-Swift Limited paid ₹0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Ind-Swift Limited stock is currently trading at ₹8.4 per share. It touched a 52-week high of ₹14.63 and a 52-week low of ₹14.63. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹8.24 and 200-day moving average was ₹9.32 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 6716.3% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Ind-Swift Limited
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Ind-Swift Limited develops pharmaceutical formulations, finished goods dosages, active pharmaceutical ingredients, and herbal products in India. It offers medicines for various therapeutic segments, such as ENT, dentistry, anti-infective, cardio-diabetic, and orthopedic therapies under the Zoxiclav, Glypar, Olmiswif, Telhim, Ozodom-DSR, Cefextil-O, Swiclo-Sp, Swifix-O, Swifix 200, Stemin, and Stemin Forte names; gynecology, pediatrics, dermatology, and GP under the Anin, Suprox, Cozy, Distone, and Oliade name; and antibiotic, anti-cold, nutraceuticals, anti-diarrheal, anti-malarial, anti-depressants, cardiology, diabetology, neurology, and oncology. The company also provides contract research and manufacturing services. It serves government dispensaries, doctors, and hospitals through retailers, stockists, and carrying and forwarding channels. The company exports its products to approximately 50 countries. Ind-Swift Limited was founded in 1983 and is based in Chandigarh, India.